US5710158A
(en)
*
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
US5714493A
(en)
*
|
1991-05-10 |
1998-02-03 |
Rhone-Poulenc Rorer Pharmaceuticals, Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US6645969B1
(en)
|
1991-05-10 |
2003-11-11 |
Aventis Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
USRE37650E1
(en)
|
1991-05-10 |
2002-04-09 |
Aventis Pharmacetical Products, Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
PH31122A
(en)
*
|
1993-03-31 |
1998-02-23 |
Eisai Co Ltd |
Nitrogen-containing fused-heterocycle compounds.
|
GB9325217D0
(en)
*
|
1993-12-09 |
1994-02-09 |
Zeneca Ltd |
Pyrimidine derivatives
|
PL315941A1
(en)
*
|
1994-02-23 |
1996-12-09 |
Pfizer |
4-heterocyclic substituted derivatives of quinazoline, methods of obtaining them and their application as anticarcinogenic agents
|
TW321649B
(de)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
EP0817775B1
(de)
*
|
1995-03-30 |
2001-09-12 |
Pfizer Inc. |
Chinazolinderivate
|
AU778961B2
(en)
*
|
1995-03-30 |
2004-12-23 |
Osi Pharmaceuticals, Inc. |
Intermediates for the preparation of 4-(substituted phenylamino)quinazoline derivatives
|
AU5343096A
(en)
*
|
1995-04-27 |
1996-11-18 |
Zeneca Limited |
Quinazoline derivatives
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
TW334434B
(en)
*
|
1995-05-16 |
1998-06-21 |
Kanebo Ltd |
Novel quinazoline compound and anti-tumor agent
|
US5639757A
(en)
*
|
1995-05-23 |
1997-06-17 |
Pfizer Inc. |
4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
GB9624482D0
(en)
*
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
US5760041A
(en)
*
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
SK285141B6
(sk)
*
|
1996-02-13 |
2006-07-07 |
Astrazeneca Uk Limited |
Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
KR100489174B1
(ko)
|
1996-03-05 |
2005-09-30 |
제네카-파마 소시에떼아노님 |
4-아닐리노퀴나졸린유도체
|
KR100545274B1
(ko)
*
|
1996-04-12 |
2006-04-12 |
워너-램버트 캄파니 엘엘씨 |
티로신키나제의비가역적억제제
|
DK0892789T4
(da)
†
|
1996-04-12 |
2010-04-06 |
Warner Lambert Co |
Irreversible inhibitorer af tyrosin kinaser
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
US6004967A
(en)
*
|
1996-09-13 |
1999-12-21 |
Sugen, Inc. |
Psoriasis treatment with quinazoline compounds
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
JP2009007364A
(ja)
*
|
1996-10-15 |
2009-01-15 |
Astrazeneca Uk Ltd |
キナゾリン誘導体
|
EP0837063A1
(de)
*
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazolinderivate
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
US6002008A
(en)
*
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
CN1195521C
(zh)
*
|
1997-05-06 |
2005-04-06 |
惠氏控股公司 |
喹唑啉化合物在治疗多囊肾病中的应用
|
US5929080A
(en)
*
|
1997-05-06 |
1999-07-27 |
American Cyanamid Company |
Method of treating polycystic kidney disease
|
ZA986729B
(en)
*
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
ZA986732B
(en)
*
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
US6251912B1
(en)
|
1997-08-01 |
2001-06-26 |
American Cyanamid Company |
Substituted quinazoline derivatives
|
TW436485B
(en)
*
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
AU8816298A
(en)
|
1997-08-22 |
1999-03-16 |
Zeneca Limited |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
US6323209B1
(en)
|
1997-11-06 |
2001-11-27 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
CA2337422C
(en)
|
1998-08-18 |
2010-11-02 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of egf-r antagonists
|
US6184226B1
(en)
*
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
SI2253620T1
(sl)
|
1998-09-29 |
2014-06-30 |
Wyeth Holdings Llc |
Substituirani 3-cianokinolini kot inhibitorji protein tirozin-kinaz
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
UA71945C2
(en)
*
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
HU228964B1
(en)
|
1999-02-10 |
2013-07-29 |
Astrazeneca Ab |
Quinazoline derivatives as angiogenesis inhibitors, process for their preparation and medicaments containing them
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
ATE398120T1
(de)
|
1999-11-05 |
2008-07-15 |
Astrazeneca Ab |
Neue quinazolin-derivate
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
UA75055C2
(uk)
*
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
EP1274692B1
(de)
|
2000-04-07 |
2006-08-02 |
AstraZeneca AB |
Chinazolinverbindungen
|
LT3143995T
(lt)
|
2001-02-19 |
2019-01-25 |
Novartis Ag |
Rapamicino darinys, skirtas plaučių vėžio gydymui
|
JP2003185064A
(ja)
*
|
2001-12-19 |
2003-07-03 |
Ge Plastics Japan Ltd |
配管部材
|
CA2473572C
(en)
|
2002-02-01 |
2011-05-10 |
Astrazeneca Ab |
Quinazoline compounds
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
EP1944026B1
(de)
|
2002-05-16 |
2013-06-26 |
Novartis AG |
Verwendung von EDG-Rezeptorbindemitteln bei Krebs
|
ATE458731T1
(de)
|
2002-12-20 |
2010-03-15 |
Pfizer Prod Inc |
Pyrimidin-derivate zur behandlung von anormalem zellwachstum
|
JP2006515871A
(ja)
*
|
2003-01-23 |
2006-06-08 |
ティー.ケイ. シグナル リミテッド |
上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用
|
AR044402A1
(es)
|
2003-05-19 |
2005-09-14 |
Irm Llc |
Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
GB0318422D0
(en)
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
US8318752B2
(en)
|
2003-09-19 |
2012-11-27 |
Astrazeneca Ab |
4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same
|
US7232824B2
(en)
*
|
2003-09-30 |
2007-06-19 |
Scios, Inc. |
Quinazoline derivatives as medicaments
|
EP2253614B1
(de)
|
2004-04-07 |
2012-09-19 |
Novartis AG |
Inhibitoren von IAP
|
CA2565812C
(en)
|
2004-05-06 |
2012-03-13 |
Warner-Lambert Company Llc |
4-phenylamino-quinazolin-6-yl-amides
|
CA2471177A1
(en)
*
|
2004-06-14 |
2005-12-14 |
Fouad Brahimi |
Novel combi-molecules having egfr and dna targeting properties
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
US20090155247A1
(en)
*
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
WO2006090163A1
(en)
|
2005-02-26 |
2006-08-31 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
CN101175733A
(zh)
*
|
2005-05-12 |
2008-05-07 |
黄文林 |
一种酪氨酸激酶抑制剂、其制备方法及作为抗肿瘤药物的应用
|
CN101175734B
(zh)
*
|
2005-05-12 |
2011-10-12 |
黄文林 |
一种作为抗肿瘤药物的喹唑啉衍生物及其制备方法
|
WO2006119675A1
(fr)
*
|
2005-05-12 |
2006-11-16 |
Wenlin Huang |
Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d'une maladie tumorale
|
CN101175732B
(zh)
|
2005-05-12 |
2010-06-16 |
黄文林 |
一种喹唑啉衍生物的制备方法及用作制备治疗肿瘤疾病药物的应用
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
KR20140012218A
(ko)
|
2005-11-21 |
2014-01-29 |
노파르티스 아게 |
Mtor 억제제를 사용하는 신경내분비 종양 치료법
|
CN101003514A
(zh)
|
2006-01-20 |
2007-07-25 |
上海艾力斯医药科技有限公司 |
喹唑啉衍生物、其制备方法及用途
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
US20070231298A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Cell Genesys, Inc. |
Cytokine-expressing cancer immunotherapy combinations
|
CA2645633A1
(en)
|
2006-04-05 |
2007-11-01 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
CN102861338A
(zh)
|
2006-04-05 |
2013-01-09 |
诺瓦提斯公司 |
用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
|
NZ572299A
(en)
|
2006-05-09 |
2010-07-30 |
Novartis Ag |
Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof
|
UA91129C2
(ru)
|
2006-05-09 |
2010-06-25 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит
|
CN101100466B
(zh)
|
2006-07-05 |
2013-12-25 |
天津和美生物技术有限公司 |
不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用
|
AU2007296745B2
(en)
*
|
2006-09-11 |
2011-12-01 |
Curis, Inc. |
Quinazoline based EGFR inhibitors
|
US20100008910A1
(en)
|
2006-09-12 |
2010-01-14 |
John Chant |
Methods and compositions for the diagnosis and treatment of cancer
|
ATE502943T1
(de)
|
2006-09-29 |
2011-04-15 |
Novartis Ag |
Pyrazolopyrimidine als pi3k-lipidkinasehemmer
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
MX2009007610A
(es)
|
2007-02-06 |
2009-07-24 |
Boehringer Ingelheim Int |
Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
|
CN101245050A
(zh)
|
2007-02-14 |
2008-08-20 |
上海艾力斯医药科技有限公司 |
4-苯胺喹唑啉衍生物的盐
|
KR20090110913A
(ko)
|
2007-02-15 |
2009-10-23 |
노파르티스 아게 |
Lbh589와 암을 치료하기 위한 다른 치료제와의 조합물
|
CA2684447C
(en)
|
2007-04-18 |
2012-01-24 |
Pfizer Products Inc. |
Sulfonyl amide derivatives for the treatment of abnormal cell growth
|
JP2011502141A
(ja)
*
|
2007-10-29 |
2011-01-20 |
ナトコ ファーマ リミテッド |
抗癌剤としての4‐(テトラゾール‐5‐イル)‐キナゾリン誘導体
|
WO2009067543A2
(en)
*
|
2007-11-19 |
2009-05-28 |
The Regents Of The University Of Colorado |
Treatment of histone deacetylase mediated disorders
|
CN101918374A
(zh)
|
2008-01-18 |
2010-12-15 |
纳特科制药有限公司 |
用于治疗癌症相关病症的6.7-二烷氧基喹唑啉衍生物
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
SI2245026T1
(sl)
|
2008-02-07 |
2012-12-31 |
Boehringer Ingelheim International Gmbh |
Spirociklični heterocikli, zdravila, ki vsebujejo te spojine, njihova uporaba in postopek za njihovo pripravo
|
DE102008009609A1
(de)
|
2008-02-18 |
2009-08-20 |
Freie Universität Berlin |
Substituierte 4-(Indol-3-yl)chinazoline und deren Verwendung und Herstellung
|
US8222424B2
(en)
|
2008-03-24 |
2012-07-17 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
AU2009228778B2
(en)
|
2008-03-26 |
2012-04-19 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases B
|
DE102008022221A1
(de)
|
2008-05-06 |
2009-11-12 |
Universität des Saarlandes |
Inhibitoren der humanen Aldosteronsynthase CYP11B2
|
BRPI0912170A2
(pt)
|
2008-05-13 |
2015-10-13 |
Astrazeneca Ab |
composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
|
WO2010015522A1
(de)
|
2008-08-08 |
2010-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
US20110223241A1
(en)
|
2008-10-16 |
2011-09-15 |
Celator Pharmaceuticals, Inc. |
Combination methods and compositions
|
EP2379499B1
(de)
|
2008-12-18 |
2014-04-09 |
Novartis AG |
Hydrochlorid Salz der 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidin-3-carbonsäure
|
CN102256942B
(zh)
|
2008-12-18 |
2013-07-24 |
诺瓦提斯公司 |
1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的多晶型物
|
KR20110096584A
(ko)
|
2008-12-18 |
2011-08-30 |
노파르티스 아게 |
1-[4-[1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸]-2-에틸-벤질]-아제티딘-3-카르복실산의 헤미푸마레이트 염
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
TW201031406A
(en)
|
2009-01-29 |
2010-09-01 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
KR20130080871A
(ko)
|
2009-03-20 |
2013-07-15 |
제넨테크, 인크. |
이중특이적 항-her 항체
|
JO2892B1
(en)
|
2009-06-26 |
2015-09-15 |
نوفارتيس ايه جي |
CYP inhibitors 17
|
US9050341B2
(en)
|
2009-07-14 |
2015-06-09 |
Natco Pharma Limited |
Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
MX2012001838A
(es)
|
2009-08-12 |
2012-02-29 |
Novartis Ag |
Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
|
MY162604A
(en)
|
2009-08-17 |
2017-06-30 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
IN2012DN01453A
(de)
|
2009-08-20 |
2015-06-05 |
Novartis Ag |
|
JP2013503129A
(ja)
|
2009-08-26 |
2013-01-31 |
ノバルティス アーゲー |
テトラ−置換ヘテロアリール化合物ならびにmdm2および/またはmdm4モジュレーターとしてのそれらの使用
|
US20120157471A1
(en)
|
2009-09-01 |
2012-06-21 |
Pfizer Inc. |
Benzimidazole derivatives
|
DK2473487T3
(en)
|
2009-09-03 |
2017-02-06 |
Bristol Myers Squibb Co |
QUINAZOLINES AS CALCIUM CHANNEL INHIBITORS
|
MY156209A
(en)
|
2009-11-04 |
2016-01-29 |
Novartis Ag |
Heterocyclic sulfonamide derivatives useful mek inhibitors
|
US8541404B2
(en)
|
2009-11-09 |
2013-09-24 |
Elexopharm Gmbh |
Inhibitors of the human aldosterone synthase CYP11B2
|
KR20120103587A
(ko)
|
2009-11-12 |
2012-09-19 |
제넨테크, 인크. |
수상돌기 소극 밀도를 증진시키는 방법
|
ES2484171T3
(es)
|
2009-12-08 |
2014-08-11 |
Novartis Ag |
Derivados de sulfonamidas heterocíclicas
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
TW201129565A
(en)
|
2010-01-12 |
2011-09-01 |
Hoffmann La Roche |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
SI2536748T1
(sl)
|
2010-02-18 |
2014-12-31 |
Genentech, Inc. |
Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka
|
CA2793024A1
(en)
|
2010-03-17 |
2011-09-22 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
CA2793892A1
(en)
|
2010-04-16 |
2011-10-20 |
Elizabeth Punnoose |
Foxo3a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
US20120089541A1
(en)
|
2010-08-31 |
2012-04-12 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
AR082974A1
(es)
|
2010-09-15 |
2013-01-23 |
Hoffmann La Roche |
Derivados de azabenzotiazol, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para tratar enfermedades inflamatorias
|
US8946260B2
(en)
|
2010-09-16 |
2015-02-03 |
Novartis Ag |
17α-hydroxylase/C17,20-lyase inhibitors
|
WO2012052948A1
(en)
|
2010-10-20 |
2012-04-26 |
Pfizer Inc. |
Pyridine- 2- derivatives as smoothened receptor modulators
|
BR112013011520A2
(pt)
|
2010-11-19 |
2019-09-24 |
Hoffmann La Roche |
pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
|
US8685993B2
(en)
|
2010-12-21 |
2014-04-01 |
Novartis Ag |
Bi-heteroaryl compounds as Vps34 inhibitors
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
EP2673277A1
(de)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
SG193291A1
(en)
|
2011-03-04 |
2013-10-30 |
Newgen Therapeutics Inc |
Alkyne substituted quinazoline compound and methods of use
|
US9029399B2
(en)
|
2011-04-28 |
2015-05-12 |
Novartis Ag |
17α-hydroxylase/C17,20-lyase inhibitors
|
EP2718276A1
(de)
|
2011-06-09 |
2014-04-16 |
Novartis AG |
Heterocyclische sulfonamidderivate
|
WO2012175487A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
MX2013015001A
(es)
|
2011-06-27 |
2014-03-31 |
Novartis Ag |
Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a.
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
BR112014003237A2
(pt)
|
2011-08-12 |
2017-04-25 |
Hoffmann La Roche |
compostos de indazol, composições e métodos de uso
|
BR112014003431A2
(pt)
|
2011-08-17 |
2017-06-13 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
|
EP2755976B1
(de)
|
2011-09-15 |
2018-07-18 |
Novartis AG |
6-substituierte 3-(chinolin-6-ylthio)-[1,2,4-]triazolo-[4,3-a-]pyradine als tyrosinkinase
|
WO2013041539A1
(en)
|
2011-09-20 |
2013-03-28 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
KR20140059246A
(ko)
|
2011-09-22 |
2014-05-15 |
화이자 인코포레이티드 |
피롤로피리미딘 및 퓨린 유도체
|
WO2013080141A1
(en)
|
2011-11-29 |
2013-06-06 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
AU2012346540C1
(en)
|
2011-11-30 |
2019-07-04 |
Genentech, Inc. |
ErbB3 mutations in cancer
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
MY170922A
(en)
|
2011-12-22 |
2019-09-18 |
Novartis Ag |
Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
AU2012355619A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
EA201491264A1
(ru)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
|
AU2012355624A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
AU2012355615A1
(en)
|
2011-12-23 |
2014-07-10 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
MX2014007729A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
JO3357B1
(ar)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
مركبات إيميدازوبيروليدينون
|
CN103254140B
(zh)
*
|
2012-02-17 |
2016-02-17 |
北京师范大学 |
新型18f标记取代喹唑啉类化合物及其制备方法和肿瘤pet显像应用
|
BR112014024017A8
(pt)
|
2012-03-27 |
2017-07-25 |
Genentech Inc |
Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
|
CN104245701A
(zh)
|
2012-04-03 |
2014-12-24 |
诺华有限公司 |
有酪氨酸激酶抑制剂的组合产品和其应用
|
JP6171003B2
(ja)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
ピロロピロリジノン化合物
|
CN104582732A
(zh)
|
2012-06-15 |
2015-04-29 |
布里格姆及妇女医院股份有限公司 |
治疗癌症的组合物及其制造方法
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
CN104994879A
(zh)
|
2013-02-22 |
2015-10-21 |
霍夫曼-拉罗奇有限公司 |
治疗癌症和预防药物抗性的方法
|
BR112015021423A2
(pt)
|
2013-03-06 |
2017-07-18 |
Genentech Inc |
métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
|
BR112015022545A2
(pt)
|
2013-03-13 |
2017-07-18 |
Constellation Pharmaceuticals Inc |
compostos de pirazolo e os usos disso
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
RU2015139054A
(ru)
|
2013-03-14 |
2017-04-19 |
Дженентек, Инк. |
Способы лечения рака и профилактики лекарственной резистентности рака
|
KR20150130451A
(ko)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
암 치료 방법 및 항암제 내성 예방을 위한 방법
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
EP3041474B1
(de)
|
2013-09-05 |
2020-03-18 |
Genentech, Inc. |
Antiproliferative verbindungen
|
EP3046921A4
(de)
|
2013-09-22 |
2017-02-22 |
Calitor Sciences, LLC |
Substituierte aminopyrimidinverbindungen und verfahren zur verwendung
|
TW201605857A
(zh)
|
2013-10-03 |
2016-02-16 |
赫孚孟拉羅股份公司 |
Cdk8之醫療性抑制劑及其用途
|
US20150147333A1
(en)
|
2013-10-18 |
2015-05-28 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
KR20160099092A
(ko)
|
2013-12-17 |
2016-08-19 |
제넨테크, 인크. |
Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
|
KR20240017102A
(ko)
|
2013-12-17 |
2024-02-06 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
JP2017516458A
(ja)
|
2014-03-24 |
2017-06-22 |
ジェネンテック, インコーポレイテッド |
c−met拮抗剤による癌治療及びc−met拮抗剤のHGF発現との相関
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
WO2015148869A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
PT3126394T
(pt)
|
2014-03-31 |
2019-12-19 |
Hoffmann La Roche |
Anticorpos anti-ox40 e métodos de utilização
|
KR20160132496A
(ko)
|
2014-04-03 |
2016-11-18 |
인빅터스 온콜로지 피비티. 엘티디. |
초분자 조합 치료제
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
MA49708A
(fr)
|
2014-04-30 |
2020-06-03 |
Pfizer |
Dérivés de dihétérocycle liés à cycloalkyle
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
AU2015294889B2
(en)
|
2014-07-31 |
2018-03-15 |
Novartis Ag |
Combination therapy
|
CN107074823B
(zh)
|
2014-09-05 |
2021-05-04 |
基因泰克公司 |
治疗性化合物及其用途
|
WO2016044694A1
(en)
|
2014-09-19 |
2016-03-24 |
Genentech, Inc. |
Use of cbp/ep300 and bet inhibitors for treatment of cancer
|
EP3204379B1
(de)
|
2014-10-10 |
2019-03-06 |
Genentech, Inc. |
Pyrrolidinamid-verbindungen als histondemethylase-inhibitoren
|
EP3215850B1
(de)
|
2014-11-03 |
2019-07-03 |
F. Hoffmann-La Roche AG |
Tests zum nachweis von te-zell-immununtergruppen und verfahren zur verwendung davon
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
CN107108613B
(zh)
|
2014-11-10 |
2020-02-25 |
基因泰克公司 |
布罗莫结构域抑制剂及其用途
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
AU2015350242A1
(en)
|
2014-11-17 |
2017-06-29 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
JP6771464B2
(ja)
|
2014-11-27 |
2020-10-21 |
ジェネンテック, インコーポレイテッド |
Cbpおよび/またはep300インヒビターとしての、4,5,6,7−テトラヒドロ−1h−ピラゾロ[4,3−c]ピリジン−3−アミン化合物
|
MX2017006864A
(es)
|
2014-12-23 |
2017-08-28 |
Genentech Inc |
Composiciones y métodos para tratar y diagnosticar cánceres resistentes a la quimioterapia.
|
EP3240908A2
(de)
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Verfahren und zusammensetzungen zur diagnose und behandlung von krebs
|
JP6659703B2
(ja)
|
2015-01-09 |
2020-03-04 |
ジェネンテック, インコーポレイテッド |
ピリダジノン誘導体および癌の処置におけるそれらの使用
|
JP6889661B2
(ja)
|
2015-01-09 |
2021-06-18 |
ジェネンテック, インコーポレイテッド |
4,5−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ(kdm2b)インヒビターとしてのその使用
|
JP6855379B2
(ja)
|
2015-01-09 |
2021-04-07 |
ジェネンテック, インコーポレイテッド |
癌の処置のためのヒストンデメチラーゼkdm2bのインヒビターとしての(ピペリジン−3−イル)(ナフタレン−2−イル)メタノン誘導体および関連化合物
|
JP6709792B2
(ja)
|
2015-01-29 |
2020-06-17 |
ジェネンテック, インコーポレイテッド |
治療用化合物およびその使用
|
CN107438593B
(zh)
|
2015-01-30 |
2020-10-30 |
基因泰克公司 |
治疗化合物及其用途
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
WO2016164480A1
(en)
|
2015-04-07 |
2016-10-13 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
IL255312B
(en)
|
2015-05-12 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
|
EP3708681A1
(de)
|
2015-05-29 |
2020-09-16 |
F. Hoffmann-La Roche AG |
Therapeutische und diagnostische verfahren für krebs
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
EP3303397A1
(de)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Verfahren zur krebsbehandlung mit anti-ox40-antikörpern und pd-1-achsen-bindungsantagonisten
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
DK3341376T3
(da)
|
2015-08-26 |
2021-03-29 |
Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio |
Kondenserede tricykliske forbindelser som proteinkinase-inhibitorer
|
EP3347097B1
(de)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituierte aminopyrimidin-derivate als modulatoren der kinasen jak, flt3 und aurora
|
RU2732591C2
(ru)
|
2015-09-25 |
2020-09-21 |
Дженентек, Инк. |
Анти-tigit антитела и способы применения
|
MX2018004109A
(es)
|
2015-10-05 |
2018-09-27 |
Univ Columbia |
Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
|
WO2017106647A1
(en)
|
2015-12-16 |
2017-06-22 |
Genentech, Inc. |
Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer
|
CN108368179B
(zh)
|
2016-01-08 |
2022-08-23 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
|
AU2017225854B2
(en)
|
2016-02-29 |
2020-11-19 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
WO2017180581A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
CN109154027A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
WO2017205536A2
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
WO2017205538A1
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Pyrazolopyridine derivatives for the treatment of cancer
|
CN109312407A
(zh)
|
2016-06-08 |
2019-02-05 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
CN107488152B
(zh)
*
|
2016-06-10 |
2020-12-29 |
山东新时代药业有限公司 |
一种阿法替尼中间体及其合成方法
|
CN107488194B
(zh)
*
|
2016-06-10 |
2021-07-30 |
山东新时代药业有限公司 |
一种阿法替尼中间体及其制备方法
|
CN107488171B
(zh)
*
|
2016-06-10 |
2020-08-28 |
山东新时代药业有限公司 |
一种阿法替尼制备方法
|
EP3494139B1
(de)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalente und multiepitopische anitikörper mit agonistischer wirkung und verfahren zur verwendung
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
KR20190072528A
(ko)
|
2016-10-06 |
2019-06-25 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
EP3532091A2
(de)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic-antikörper und verfahren zur verwendung
|
US11040984B2
(en)
*
|
2016-12-30 |
2021-06-22 |
Medshine Discovery Inc. |
Quinazoline compound for EGFR inhibition
|
TW201837467A
(zh)
|
2017-03-01 |
2018-10-16 |
美商建南德克公司 |
用於癌症之診斷及治療方法
|
BR112019021411A2
(pt)
|
2017-04-13 |
2020-05-05 |
Hoffmann La Roche |
métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
|
TWI823859B
(zh)
|
2017-07-21 |
2023-12-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
AU2018316343A1
(en)
|
2017-08-11 |
2020-02-13 |
Genentech, Inc. |
Anti-CD8 antibodies and uses thereof
|
AU2018329925A1
(en)
|
2017-09-08 |
2020-03-05 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
EP3710001A4
(de)
|
2017-10-27 |
2021-07-14 |
University Of Virginia Patent Foundation |
Verbindungen und verfahren zur regulierung, begrenzung oder hemmung der avil-expression
|
EP3707510B1
(de)
|
2017-11-06 |
2024-06-26 |
F. Hoffmann-La Roche AG |
Diagnose- und therapieverfahren für krebs
|
JP7254076B2
(ja)
|
2017-11-19 |
2023-04-07 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
置換ヘテロアリール化合物及び使用方法
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
CA3092108A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2019226514A2
(en)
|
2018-05-21 |
2019-11-28 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
CA3103017A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
WO2020007219A1
(zh)
*
|
2018-07-02 |
2020-01-09 |
南京明德新药研发有限公司 |
一种egfr抑制剂的晶型及其制备方法
|
MX2021000558A
(es)
|
2018-07-18 |
2021-04-13 |
Genentech Inc |
Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino.
|
WO2020051099A1
(en)
|
2018-09-03 |
2020-03-12 |
Genentech, Inc. |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
WO2020061060A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
CA3111809A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
EP3898626A1
(de)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
Substituierte pyrazolo[1,5-a]pyridin-verbindungen als inhibitoren von fgfr-tyrosinkinasen
|
JP2022515197A
(ja)
|
2018-12-19 |
2022-02-17 |
アレイ バイオファーマ インコーポレイテッド |
がんを治療するためのfgfr阻害剤としての7-((3,5-ジメトキシフェニル)アミノ)キノキサリン誘導体
|
WO2020163589A1
(en)
|
2019-02-08 |
2020-08-13 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬
|
CN113677994A
(zh)
|
2019-02-27 |
2021-11-19 |
外延轴治疗股份有限公司 |
用于评估t细胞功能和预测对疗法的应答的方法和药剂
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
WO2020226986A2
(en)
|
2019-05-03 |
2020-11-12 |
Genentech, Inc. |
Methods of treating cancer with an anti-pd-l1 antibody
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
MX2022002738A
(es)
|
2019-09-04 |
2022-06-27 |
Genentech Inc |
Agentes de union a cd8 y uso de los mismos.
|
AU2020351734A1
(en)
|
2019-09-27 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
|
WO2021083949A1
(en)
|
2019-10-29 |
2021-05-06 |
F. Hoffmann-La Roche Ag |
Bifunctional compounds for the treatment of cancer
|
KR20220092580A
(ko)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
혈액암의 치료를 위한 진단과 치료 방법
|
KR20220101138A
(ko)
|
2019-11-13 |
2022-07-19 |
제넨테크, 인크. |
치료적 화합물 및 사용 방법
|
AU2020403145A1
(en)
|
2019-12-13 |
2022-07-07 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
WO2021127404A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
TW202142230A
(zh)
|
2020-01-27 |
2021-11-16 |
美商建南德克公司 |
用於以抗tigit拮抗體抗體治療癌症之方法
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
AU2021293038A1
(en)
|
2020-06-16 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating triple-negative breast cancer
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
CN116568824A
(zh)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
淋巴瘤的诊断和治疗方法
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
WO2022066805A1
(en)
|
2020-09-23 |
2022-03-31 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
JP2024506339A
(ja)
|
2021-02-12 |
2024-02-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための二環式テトラヒドロアゼピン誘導体
|
KR20240026948A
(ko)
|
2021-05-25 |
2024-02-29 |
에라스카, 아이엔씨. |
황 함유 헤테로방향족 트리사이클릭 kras 억제제
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
TW202321261A
(zh)
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
選擇性kras抑制劑
|
US20230203062A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|